Antiangiogenic therapy for breast cancer

24 Citationer (Scopus)

Abstract

ABSTRACT: Angiogenesis is an important component of cancer growth, invasion and metastasis. Therefore, inhibition of angiogenesis is an attractive strategy for treatment of cancer. We describe existing clinical trials of antiangiogenic agents and the challenges facing the clinical development and optimal use of these agents for the treatment of breast cancer. Currently, the most promising approach has been the use of bevacizumab, a humanized monoclonal antibody directed against the most potent pro-angiogenic factor, vascular endothelial growth factor (VEGF). Small molecular inhibitors of VEGF tyrosine kinase activity, such as sorafenib, appear promising. While, the role of sunitinib and inhibitors of mammalian target of rapamycin (mTOR) in breast cancer has to be defined. Several unanswered questions remain, such as choice of drug(s), optimal duration of therapy and patient selection criteria
OriginalsprogEngelsk
TidsskriftBreast Cancer Research (Online Edition)
Vol/bind12
Udgave nummer5
Sider (fra-til)209
Antal sider1
ISSN1465-542X
DOI
StatusUdgivet - 2010

Citationsformater